Rezulin return unlikely

Pfizer has no plans to reintroduce the Type 2 diabetes therapy Rezulin, the company said. At the recent Pharmaceutical Research & Manufacturers of America annual meeting, Agency for Healthcare Research & Quality Director Carolyn Clancy commented during a panel discussion on data she recently saw suggesting that Rezulin had no greater risk of liver toxicity than the background rate. Clancy speculated that the product could be a candidate for reintroduction, based on that data. Rezulin (troglitazone) was withdrawn by Warner-Lambert in 2000 after FDA concluded that two competing agents, Actos and Avandia, have a better safety profile...